Pharvaris (NASDAQ:PHVS) Insider Wim Souverijns Sells 6,090 Shares of Stock

Pharvaris N.V. (NASDAQ:PHVS) insider Wim Souverijns sold 6,090 shares of the firm’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $38.99, for a total value of $237,449.10. Following the transaction, the insider owned 39,021 shares of the company’s stock, valued at $1,521,428.79. This trade represents a 13.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Wim Souverijns also recently made the following trade(s):

• On Monday, September 14th, Wim Souverijns sold 20,000 shares of Pharvaris stock. The shares were sold at an average price of $39.31, for a total transaction of $786,200.00.

Pharvaris Trading Down 1.3%

NASDAQ:PHVS opened at $37.55 on Thursday. The firm has a market cap of $2.46 billion, a PE ratio of -12.31 and a beta of -2.33. The stock has a fifty day moving average price of $35.31 and a 200 day moving average price of $31.63. Pharvaris N.V. has a 12-month low of $20.65 and a 12-month high of $43.25.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Equities analysts forecast that Pharvaris N.V. will post -3.12 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. Guggenheim increased their price objective on shares of Pharvaris from $40.00 to $44.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. Oppenheimer reaffirmed an “outperform” rating and set a $75.00 price objective on shares of Pharvaris in a research report on Tuesday, September 8th. Citizens Jmp boosted their target price on shares of Pharvaris from $75.00 to $79.00 and gave the stock a “market outperform” rating in a research note on Wednesday, September 9th. New Street Research set a $60.00 target price on Pharvaris in a report on Friday, August 14th. Finally, Wells Fargo & Company lifted their price target on Pharvaris from $55.00 to $65.00 and gave the stock an “overweight” rating in a report on Wednesday, September 9th. Thirteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Pharvaris presently has a consensus rating of “Moderate Buy” and an average price target of $59.87.

More Pharvaris News

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Pharvaris’ phase III data showed that once-daily extended-release deucrictibant reduced hereditary angioedema attacks by 83%. The result strengthens the case for the company’s lead drug and supports planned regulatory submissions in 2027. PHVS Stock Rises 10% in a Month: What Is Driving the Rally?
• Positive Sentiment: Analyst expectations remain favorable. The reported consensus price target rose 20.08% to $59.77, while recent targets include $62 from RBC and $65 from Wells Fargo and Leerink Partners. The broader analyst consensus is “Moderate Buy.” Pharvaris Consensus Price Target Raised
• Positive Sentiment: Recent institutional activity has been supportive, including a new BlackRock position and larger holdings from Alyeska Investment Group and Seven Fleet Capital, suggesting increased professional-investor interest.
• Neutral Sentiment: Pharvaris presented at the Morgan Stanley 24th Annual Global Healthcare Conference. The event provided management with an opportunity to discuss deucrictibant and its regulatory strategy, but the supplied transcript does not identify a separate new announcement. Pharvaris Morgan Stanley Conference Transcript
• Negative Sentiment: Insider selling is weighing on sentiment. Insider Wim Souverijns sold 26,090 shares for approximately $1.02 million across September 14–15, while CEO Berndt Modig sold 2,291 shares worth about $90,265. President Peng Lu also sold 15,000 shares for roughly $602,000 to cover tax withholding related to vested equity awards. Anne Lesage separately sold 30,000 shares for approximately $1.15 million. Although some sales were tax-related and insiders retain significant holdings, the volume of selling can raise concerns about near-term supply and insider confidence. Pharvaris Insider Selling

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. venBio Partners LLC acquired a new stake in shares of Pharvaris during the second quarter worth about $160,569,809. Wellington Management Group LLP lifted its holdings in shares of Pharvaris by 12.9% during the second quarter. Wellington Management Group LLP now owns 2,392,934 shares of the company’s stock worth $82,748,000 after purchasing an additional 274,034 shares during the period. Commodore Capital LP lifted its holdings in shares of Pharvaris by 1.6% during the first quarter. Commodore Capital LP now owns 1,918,970 shares of the company’s stock worth $54,211,000 after purchasing an additional 29,525 shares during the period. 5AM Venture Management LLC purchased a new position in Pharvaris in the 2nd quarter valued at $27,581,008. Finally, Seven Fleet Capital Management LP increased its stake in Pharvaris by 144.6% in the 2nd quarter. Seven Fleet Capital Management LP now owns 774,501 shares of the company’s stock valued at $26,782,000 after buying an additional 457,804 shares during the period.

Pharvaris Company Profile

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.